Form 4: Director Irit Arbel Receives 120,000 BCLI Shares

BrainStorm Cell Therapeutics director Irit Arbel was granted 120,000 restricted stock units as part of the company's 2014 Global Share Option Plan.

Summary

• Director Irit Arbel acquired 120,000 shares of BrainStorm Cell Therapeutics (BCLI) common stock via restricted stock units (RSUs).
• The transaction occurred on February 26, 2026.
• The acquisition price for the units was $0.00.
• Following this transaction, the reporting person's total beneficial ownership increased to 161,054 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine regulatory disclosure regarding director compensation, which is neutral in terms of immediate market impact.

Positives

• The grant of equity aligns the director's interests with those of the shareholders.

Negatives

• The issuance of additional equity results in potential dilution for existing shareholders.

Risks

• Vesting is contingent upon the reporting person remaining employed by the issuer through the specified dates.

Future Outlook

The RSUs vest in two tranches: 50% on the grant date and 50% on the six-month anniversary of the grant date, subject to continued service.

Industry Context

StockSavvy.ai notes that equity-based compensation for directors is a standard practice in the biotechnology sector to incentivize long-term strategic oversight and retention of key leadership.

Comparison to Industry Standards

• The use of RSU grants for board members is consistent with standard corporate governance practices for small-cap biotech firms.
• Vesting schedules of six months to one year are common for director compensation in the industry.

Stakeholder Impact

• Shareholders may experience minor dilution due to the issuance of new equity.

Next Steps

• Vesting of the remaining 50% of the RSU award on August 26, 2026, provided the director remains with the company.

Key Dates

Keywords

BrainStorm Cell Therapeutics, BCLI, Insider Trading, Form 4, Equity Compensation, Biotech